{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-316819","form_type":"8-K","ticker":"NMRA","cik":"0001885522","company_name":"Neumora Therapeutics, Inc.","filed_at":"2026-07-27T11:07:30+00:00","discovered_at":"2026-07-27T11:10:00.294288+00:00","generated_at":"2026-07-27T11:10:11.735549+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Neumora Therapeutics reports favorable NMRA-215 toxicology results, plans IND in Q4 2026","bullets":["Repeat 13-week rat toxicology study (162 animals) showed no unexpected adverse findings, resolving prior concerns from a study with 5 of 142 animals affected.","Company plans to submit IND for NMRA-215, an oral NLRP3 inhibitor for obesity and cardiometabolic disease, in Q4 2026 and start Phase 1 by end of 2026.","NMRA-215 demonstrated class-leading weight loss in diet-induced obesity mouse model, including additive effects with semaglutide and potential for switch/maintenance.","For-cause audit of prior study revealed discrepancies; company believes prior adverse findings were not drug-related."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-316819","json":"https://secwatch.observer/filing/0001193125-26-316819.json","markdown":"https://secwatch.observer/filing/0001193125-26-316819.md","text":"https://secwatch.observer/filing/0001193125-26-316819.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1885522/000119312526316819/0001193125-26-316819-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1885522/000119312526316819/nmra-20260727.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-27T11:10:11.735549+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}